Business Context and Reporting Period
Company: Danaher Corporation (DHR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Danaher is a global science and technology innovator operating in three segments: Biotechnology, Life Sciences, and Diagnostics. The company serves the biopharmaceutical, life sciences research, and clinical diagnostics markets through a portfolio of over 15 operating companies. As of December 31, 2025, the company employed approximately 60,000 associates globally.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Sales | $24,568 million | $23,875 million | +3.0% |
| Core Sales Growth (Non-GAAP) | 2.0% | -1.5% | N/A |
| Operating Profit | $4,690 million | $4,863 million | -3.6% |
| Operating Margin | 19.1% | 20.4% | -130 bps |
| Net Earnings (Continuing Ops) | $3,600 million | $3,899 million | -7.7% |
| Diluted EPS (Continuing Ops) | $5.03 | $5.29 | -4.9% |
| Operating Cash Flow | $6,416 million | $6,688 million | -4.1% |
| Total Debt | $18,418 million | $16,005 million | +15.1% |
| Cash and Equivalents | $4,615 million | $2,078 million | +122.1% |
Material Changes vs. Prior Period
- Revenue Performance: Total sales increased 3.0% year-over-year, driven by a 2.0% increase in core sales and a 1.0% positive impact from currency translation. Biotechnology sales grew 8.0%, while Life Sciences remained flat and Diagnostics grew 1.5%.
- Profitability Decline: Operating profit margins decreased 130 basis points to 19.1%. This was primarily due to $562 million in impairment charges (compared to $265 million in 2024), higher costs related to productivity improvements, and the dilutive effect of acquired businesses.
- Impairment Charges: Significant non-cash impairment charges were recorded in 2025, including a $432 million charge related to a trade name in the Life Sciences segment and charges in Biotechnology and Diagnostics segments related to technology and facilities.
- Tariff Impact: The company incurred incremental tariff costs of less than $300 million in 2025 due to new U.S. tariffs. Management largely offset the operating profit impact through supply chain adjustments and price increases.
- Capital Structure: Total debt increased to approximately $18.4 billion, reflecting new borrowings including a $1.6 billion Swiss franc bond issuance in October 2025. Cash and equivalents rose significantly to $4.6 billion.
Guidance, Outlook, and Risks
- 2026 Outlook:
- Biotechnology: Assumes sales growth trends similar to 2025, driven by consumables demand.
- Life Sciences: Anticipates modest improvement in end markets but expects sales growth rates to remain below historical levels due to the macro environment.
- Diagnostics: Assumes higher sales growth in 2026 as the company moves past headwinds from policy changes in China.
- Tax Rate: The 2026 effective tax rate is expected to be approximately 17.0%, higher than the 15.0% rate in 2025 due to the absence of certain discrete tax benefits.
- Pending Acquisition: On February 16, 2026, Danaher entered into an agreement to acquire Masimo Corporation for approximately $9.9 billion. The transaction is subject to regulatory approvals and shareholder votes.
- Key Risks:
- Trade Policy: Uncertainty regarding U.S. tariffs and retaliatory measures, including a February 2026 Supreme Court ruling on the administration's authority to impose tariffs.
- Geopolitical: Ongoing conflicts (Russia/Ukraine, Middle East) and economic conditions in China (11% of 2025 sales).
- Regulatory: Extensive healthcare regulation (FDA, EU MDR/IVDR) and potential changes in reimbursement policies.
- Intangible Assets: Risk of future impairment charges if market conditions or trading multiples deteriorate.
Investor Verification Checklist
- Impairment Sustainability: Verify the assumptions used in the $562 million impairment charges, particularly the $432 million Life Sciences trade name write-down, to assess if further write-downs are likely.
- Tariff Exposure: Monitor the impact of the February 2026 Supreme Court ruling on tariffs and the company's ability to pass on costs without losing market share.
- Masimo Acquisition: Track regulatory approval status and integration plans for the pending $9.9 billion Masimo acquisition.
- Life Sciences Recovery: Assess the timeline for recovery in the Life Sciences segment, which saw flat sales and significant margin compression due to lower funding in biotech and academic markets.
- Debt Servicing: Review the company's ability to service increased debt levels ($18.4 billion) while maintaining capital returns (dividends and buybacks) in a potentially higher interest rate environment.